Medicolegal review of methotrexate administration to viable intrauterine pregnancies

Carlos A. Garcia-Jasso, Gokhan Kilic, Tony Wen, Russell Snyder, Sangeeta Jain, John Phelps

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To examine 3 legal cases in which physicians prescribed methotrexate to women with a viable intrauterine pregnancy, presumed to be ectopic, resulting in adverse fetal outcomes. STUDY DESIGN: We conducted an electronic literature search for legal cases using the keywords “methotrexate” and “pregnancy” in the LexisNexis legal research engine as well as an Internetwide search using the additional keyword “verdict.” We manually searched the resultant list of identified cases and categorized the studies identified in the search by verdict, award amount, and outcome of the embryo exposed to methotrexate. RESULTS: The monetary awards are typically greater when the embryo exposed to methotrexate lives and requires continuous medical and custodial care as compared to when the fetus dies in utero or shortly after birth. CONCLUSION: Physicians who, with all good intentions, prescribe methotrexate to women with a viable pregnancy, presumed to be ectopic, could find themselves liable for an adverse fetal outcome. For the benefit of patients, their unborn offspring, and the liability exposure of the physician, it is important to be very cautious when prescribing methotrexate.

Original languageEnglish (US)
Pages (from-to)97-101
Number of pages5
JournalJournal of Reproductive Medicine
Volume62
Issue number2
StatePublished - Apr 1 2017

Fingerprint

Methotrexate
Pregnancy
Physicians
Custodial Care
Embryonic Structures
Fetus
Parturition
Research

Keywords

  • Ectopic pregnancy
  • Lawsuits
  • Legal outcomes
  • Litigation
  • Medicolegal aspects
  • Methotrexate
  • Pregnancy
  • Pregnancy, extrauterine

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Cite this

Medicolegal review of methotrexate administration to viable intrauterine pregnancies. / Garcia-Jasso, Carlos A.; Kilic, Gokhan; Wen, Tony; Snyder, Russell; Jain, Sangeeta; Phelps, John.

In: Journal of Reproductive Medicine, Vol. 62, No. 2, 01.04.2017, p. 97-101.

Research output: Contribution to journalArticle

@article{9410fe2f92004c5fa84d3f2bccca7649,
title = "Medicolegal review of methotrexate administration to viable intrauterine pregnancies",
abstract = "OBJECTIVE: To examine 3 legal cases in which physicians prescribed methotrexate to women with a viable intrauterine pregnancy, presumed to be ectopic, resulting in adverse fetal outcomes. STUDY DESIGN: We conducted an electronic literature search for legal cases using the keywords “methotrexate” and “pregnancy” in the LexisNexis legal research engine as well as an Internetwide search using the additional keyword “verdict.” We manually searched the resultant list of identified cases and categorized the studies identified in the search by verdict, award amount, and outcome of the embryo exposed to methotrexate. RESULTS: The monetary awards are typically greater when the embryo exposed to methotrexate lives and requires continuous medical and custodial care as compared to when the fetus dies in utero or shortly after birth. CONCLUSION: Physicians who, with all good intentions, prescribe methotrexate to women with a viable pregnancy, presumed to be ectopic, could find themselves liable for an adverse fetal outcome. For the benefit of patients, their unborn offspring, and the liability exposure of the physician, it is important to be very cautious when prescribing methotrexate.",
keywords = "Ectopic pregnancy, Lawsuits, Legal outcomes, Litigation, Medicolegal aspects, Methotrexate, Pregnancy, Pregnancy, extrauterine",
author = "Garcia-Jasso, {Carlos A.} and Gokhan Kilic and Tony Wen and Russell Snyder and Sangeeta Jain and John Phelps",
year = "2017",
month = "4",
day = "1",
language = "English (US)",
volume = "62",
pages = "97--101",
journal = "The Journal of reproductive medicine",
issn = "0024-7758",
publisher = "Donna Kessel",
number = "2",

}

TY - JOUR

T1 - Medicolegal review of methotrexate administration to viable intrauterine pregnancies

AU - Garcia-Jasso, Carlos A.

AU - Kilic, Gokhan

AU - Wen, Tony

AU - Snyder, Russell

AU - Jain, Sangeeta

AU - Phelps, John

PY - 2017/4/1

Y1 - 2017/4/1

N2 - OBJECTIVE: To examine 3 legal cases in which physicians prescribed methotrexate to women with a viable intrauterine pregnancy, presumed to be ectopic, resulting in adverse fetal outcomes. STUDY DESIGN: We conducted an electronic literature search for legal cases using the keywords “methotrexate” and “pregnancy” in the LexisNexis legal research engine as well as an Internetwide search using the additional keyword “verdict.” We manually searched the resultant list of identified cases and categorized the studies identified in the search by verdict, award amount, and outcome of the embryo exposed to methotrexate. RESULTS: The monetary awards are typically greater when the embryo exposed to methotrexate lives and requires continuous medical and custodial care as compared to when the fetus dies in utero or shortly after birth. CONCLUSION: Physicians who, with all good intentions, prescribe methotrexate to women with a viable pregnancy, presumed to be ectopic, could find themselves liable for an adverse fetal outcome. For the benefit of patients, their unborn offspring, and the liability exposure of the physician, it is important to be very cautious when prescribing methotrexate.

AB - OBJECTIVE: To examine 3 legal cases in which physicians prescribed methotrexate to women with a viable intrauterine pregnancy, presumed to be ectopic, resulting in adverse fetal outcomes. STUDY DESIGN: We conducted an electronic literature search for legal cases using the keywords “methotrexate” and “pregnancy” in the LexisNexis legal research engine as well as an Internetwide search using the additional keyword “verdict.” We manually searched the resultant list of identified cases and categorized the studies identified in the search by verdict, award amount, and outcome of the embryo exposed to methotrexate. RESULTS: The monetary awards are typically greater when the embryo exposed to methotrexate lives and requires continuous medical and custodial care as compared to when the fetus dies in utero or shortly after birth. CONCLUSION: Physicians who, with all good intentions, prescribe methotrexate to women with a viable pregnancy, presumed to be ectopic, could find themselves liable for an adverse fetal outcome. For the benefit of patients, their unborn offspring, and the liability exposure of the physician, it is important to be very cautious when prescribing methotrexate.

KW - Ectopic pregnancy

KW - Lawsuits

KW - Legal outcomes

KW - Litigation

KW - Medicolegal aspects

KW - Methotrexate

KW - Pregnancy

KW - Pregnancy, extrauterine

UR - http://www.scopus.com/inward/record.url?scp=85015670363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015670363&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85015670363

VL - 62

SP - 97

EP - 101

JO - The Journal of reproductive medicine

JF - The Journal of reproductive medicine

SN - 0024-7758

IS - 2

ER -